Rznomics was introduced in the Nature Biotechnology Journal. We are proud to be introduced as one of the leading RNA editing companies in the Nature Biotechnology Journal. The article mentioned one of the advantages of the trans-splicing ribozyme, such as the capability of large-scale changes that can be introduced in a mature mRNA transcript. The article also mentioned our RZ-001 (HCC) IND approval from both MFDS & FDA. Rznomics is currently running the P1/2a trial in South Korea.

Please find the details about the attached article and the following link!